RE:RE:The path, the daisy chain of events...The 40 million dose immune booster plant had a $100 million net present value with a 20% discount rate. If CZO achieves small-scale production in the next 7 months and reaches the decision point concerning mass industrialization with the 100L facility what could the net present value of the immune booster plant be worth? AEZS could provide capital to execute and a NASDAQ platform for visibility. The PGX-YBG/fibrosis drug was also said to be a 6 month study from a clinical trial decision as PGX-CoQ10 nears a potential partnering decision in a much larger market than for yeast beta glucan as an immune booster.
Commissioning of 5X PGX scale-up expected this month.
Commissioning of 10X scale-up to decision point for mass industrialization of PGX expected in the next seven months.
PGX-yeast beta glucan: "...this product could be offered as an immune booster before year end 2024."